Loading…
Abbott and Alere announced amended terms for Abbott's pending acquisition of Alere. Abbott will pay $51 per share for an expected equity value of $5.3 billion, down from $5.8 billion. The companies have dismissed lawsuits against each other and extended the regulatory approval deadline to September 30, 2017.
The European Commission approved Abbott Laboratories' $25 billion cash-and-stock acquisition of St. Jude Medical, conditional on Abbott divesting two devices used in cardiovascular treatments.